Metraipolis › archive › dc_54ffb68b7e63

JAK inhibitors and adverse cardiovascular events: Class effect or molecule-specific risk? — Europe PMC PMID:42774336

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42774336
DOI
10.3389/fphar.2026.1896980
License (as archived)
solo-consultazione
Archived
2026-10-16T00:37:55.717Z
SHA-256 of the archived text
c662c57d3bf0ef936e6a51a594be8411c613810fd0c168993f8a1e185b32e73d
Stable URL of this page
https://metraipolis.com/documento/dc_54ffb68b7e63

How to cite

JAK inhibitors and adverse cardiovascular events: Class effect or molecule-specific risk? — Europe PMC PMID:42774336 — Europe PMC (en), https://europepmc.org/article/MED/42774336 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_54ffb68b7e63 (Metraipolis archive dc_54ffb68b7e63, sha256 c662c57d3bf0ef936e6a51a594be8411c613810fd0c168993f8a1e185b32e73d)
BibTeX
@misc{dc54ffb68b7e63,
  title = {JAK inhibitors and adverse cardiovascular events: Class effect or molecule-specific risk? — Europe PMC PMID:42774336},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42774336},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_54ffb68b7e63; sha256 c662c57d3bf0ef936e6a51a594be8411c613810fd0c168993f8a1e185b32e73d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42774336. Agents can read the archived copy with the MCP tool read_document.